Tozasertib (VX-680, MK-0457)

Name: Tozasertib (VX-680, MK-0457)
Brand: Selleck Chemicals
SKU: S1048
Rating: 5 (76 reviews)

For research use only.

Catalog No.S1048

76 publications

Tozasertib (VX-680, MK-0457) Chemical Structure

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Selleck's Tozasertib (VX-680, MK-0457) has been cited by 76 publications

Nature, 2018, 559(7713):211-216

PubMed: 29973724 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 142(3):444-55

PubMed: 20691903 ( click the link to review the publication )

EMBO Rep, 2020, 3;21(4):e49700

PubMed: 32030856 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(4):1008-1017

PubMed: 31848297 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31652588 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):432

PubMed: 31160567 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Analyst, 2019, 145(1):97-106

PubMed: 31746831 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, doi: 101016/jjpba2019112962

PubMed: 31711864 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

SLAS Discov, 2018, 23(2):132-143

PubMed: 28957641 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):1004-1010

PubMed: 30080692 ( click the link to review the publication )

Neuron, 2017, 94(6):1142-1154

PubMed: 28641113 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )
Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

EMBO J, 2016, 35(8):803-19

PubMed: 26929011 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(50):14366-14371

PubMed: 28182563 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):819-26

PubMed: 27373675 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Exp Hematol, 2016, 44(3):189-93

PubMed: 26706195 ( click the link to review the publication )

Tumour Biol, 2016, 37(11):14745-14755

PubMed: 27629142 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

Oncol Rep, 2015, 34(2):803-10

PubMed: 26044736 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(6):1354-64

PubMed: 25873592 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncol Lett, 2014, 7(1):121-124

PubMed: 24348832 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(11):1326-36

PubMed: 24008673 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )

Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )
Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Targets

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150 nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. ^[2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	NI\JR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2faSGlEPTB;MD6wNFM{QCEQvF2=	NHrSbGdUSU6JUlXS
RS4-11	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL5TWM2OD1yLkCwOFA1KM7:TR?=	MVzTRW5IWkWU
MFH-ino	M1HIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3pW214UUN3ME2wMlAxQTlizszN	MnTjV2FPT1KHUh?=
NTERA-S-cl-D1	NEnRXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFW3NoNKSzVyPUCuNFE1OzRizszN	MXPTRW5IWkWU
697	NF;ifnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnmxTWM2OD1yLkCyOFcyKM7:TR?=	MULTRW5IWkWU
NALM-6	M1y3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEK1OVIh\|ryP	M{i5eHNCVkeURWK=
ES8	NXHDXHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMES2NVMh\|ryP	MWXTRW5IWkWU
HUTU-80	MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzaTFVKSzVyPUCuNFUzQTlizszN	MUDTRW5IWkWU
MV-4-11	MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUf4UIZuUUN3ME2wMlA4Pzh{IN88US=>	MV;TRW5IWkWU
MONO-MAC-6	M37kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMEe4O\|kh\|ryP	NHzTSWxUSU6JUlXS
LC-2-ad	M4DGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXGeYZuUUN3ME2wMlA5Pzh7IN88US=>	NWTNTGhxW0GQR2LFVi=>
BL-41	NFXuV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jHeGlEPTB;MD6xNFQ1PSEQvF2=	Mon5V2FPT1KHUh?=
A4-Fuk	NH;DfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMUG1OlMh\|ryP	NUeyR\|FxW0GQR2LFVi=>
SW954	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMUKyNlkh\|ryP	MkfYV2FPT1KHUh?=
BV-173	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknFTWM2OD1yLkGyOlQyKM7:TR?=	NILhTmhUSU6JUlXS
TE-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXITWM2OD1yLkG0PVgzKM7:TR?=	M{TLc3NCVkeURWK=
SK-UT-1	NF[5RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMUW5OlUh\|ryP	NH7FfphUSU6JUlXS
SIG-M5	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHiTmpKSzVyPUCuNVY4ODdizszN	NUPD[2pnW0GQR2LFVi=>
OCUB-M	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXYR2NKSzVyPUCuNVY6QDNizszN	M1jBWHNCVkeURWK=
K052	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfaVmtKSzVyPUCuNVk1QCEQvF2=	MYPTRW5IWkWU
VA-ES-BJ	M3;PNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMkCwPFYh\|ryP	M2eyfHNCVkeURWK=
SW982	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\MdG9KSzVyPUCuNlE{QCEQvF2=	MVnTRW5IWkWU
LB647-SCLC	NH;MV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CwfWlEPTB;MD6yNVUzOyEQvF2=	MkjyV2FPT1KHUh?=
PSN1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPpTWM2OD1yLkKyNFI3KM7:TR?=	MUjTRW5IWkWU
BB30-HNC	NYfCO5lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\1TWM2OD1yLkKyOVkyKM7:TR?=	NWDDT2NkW0GQR2LFVi=>
ST486	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTBTWM2OD1yLkKzNFg4KM7:TR?=	MomzV2FPT1KHUh?=
MOLT-4	NWWxU5J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Xqd2lEPTB;MD6yN\|M{PyEQvF2=	MXPTRW5IWkWU
EW-16	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMkO3Olgh\|ryP	Mn3FV2FPT1KHUh?=
KS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInBVHJKSzVyPUCuNlM4QDVizszN	NGDzN3RUSU6JUlXS
SR	NIe0R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT4b4VUUUN3ME2wMlI1PTZ2IN88US=>	MWHTRW5IWkWU
KM12	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMk[zOkDPxE1?	M2XU[HNCVkeURWK=
EM-2	MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlX1TWM2OD1yLkK2OlQyKM7:TR?=	M3HX[HNCVkeURWK=
MEG-01	NFPHelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnaTWM2OD1yLkK3PFQ6KM7:TR?=	NUfvXllFW0GQR2LFVi=>
NB13	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPiNmNKSzVyPUCuNlc6QDRizszN	NWLsfXBJW0GQR2LFVi=>
RKO	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwM{C4NVMh\|ryP	M1O3d3NCVkeURWK=
CESS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHq3NXVKSzVyPUCuN\|E{OjhizszN	NXKzO\|V1W0GQR2LFVi=>
EoL-1-cell	NVuxOVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\t[mlEPTB;MD6zN\|Q2QSEQvF2=	M1uxeHNCVkeURWK=
DOHH-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;kV2lEPTB;MD6zN\|c5OSEQvF2=	NUX2cnNDW0GQR2LFVi=>
A388	M2LtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwM{SwPFYh\|ryP	MonhV2FPT1KHUh?=
LAMA-84	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwM{WxO\|gh\|ryP	M1XENXNCVkeURWK=
IMR-5	NVXTcXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;CVGtCUUN3ME2wMlM2PTRizszN	MXfTRW5IWkWU
KARPAS-422	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3OTWM2OD1yLkO3NlczKM7:TR?=	NFm4ToZUSU6JUlXS
MRK-nu-1	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D3NWlEPTB;MD6zPFE{KM7:TR?=	NIrtUJVUSU6JUlXS
BL-70	MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPUU3NNUUN3ME2wMlM5QTd2IN88US=>	NH7HbJNUSU6JUlXS
LXF-289	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwNEC0NFYh\|ryP	MWTTRW5IWkWU
RL95-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDxWVR2UUN3ME2wMlQxPTZ5IN88US=>	NHi1NJJUSU6JUlXS
QIMR-WIL	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXReoMzUUN3ME2wMlQzPjd4IN88US=>	MV3TRW5IWkWU
K-562	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDTdGRXUUN3ME2wMlQ{PDd{IN88US=>	M1ewN3NCVkeURWK=
NCI-H510A	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInSbohKSzVyPUCuOFM5OjNizszN	NX\V[4ZwW0GQR2LFVi=>
NCI-H524	NWDyUHZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNUGxOFch\|ryP	M3ywbXNCVkeURWK=
KE-37	NVTNNoFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\JZWlEPTB;MD61NlExOiEQvF2=	NYnNUFRNW0GQR2LFVi=>
KP-N-YS	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwNUSzPVIh\|ryP	NUnScYhrW0GQR2LFVi=>
LS-411N	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwNUe3OVIh\|ryP	MUnTRW5IWkWU
CTV-1	M2nxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTodpN5UUN3ME2wMlU5Pzd\|IN88US=>	NEXVV5JUSU6JUlXS
NCI-SNU-16	MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVX2S2hvUUN3ME2wMlY{PTdzIN88US=>	MUHTRW5IWkWU
HT-144	NEH3TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwNkO3PVgh\|ryP	NXfuTHk1W0GQR2LFVi=>
NCI-H187	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fmb2lEPTB;MD62OFE{KM7:TR?=	MUPTRW5IWkWU
OCI-AML2	NIOzVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHIXHo4UUN3ME2wMlY1PDB\|IN88US=>	NFLFUINUSU6JUlXS
CCRF-CEM	M2XnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwNkWzOFYh\|ryP	NID5SYVUSU6JUlXS
ONS-76	NFi3RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnMTWM2OD1yLk[2OFU5KM7:TR?=	NGPQcWxUSU6JUlXS
IST-SL2	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwN{G5PFIh\|ryP	NVPzXoVkW0GQR2LFVi=>
NB6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf6TWM2OD1yLke3NlU1KM7:TR?=	MljiV2FPT1KHUh?=
SK-PN-DW	NVy3d\|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\0c3JKSzVyPUCuO\|kyPCEQvF2=	MnLPV2FPT1KHUh?=
HCC1599	NF;HOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\vd2pKSzVyPUCuPFA5PzRizszN	MWnTRW5IWkWU
MC116	NGSwdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfST2pUUUN3ME2wMlg2ODFzIN88US=>	MlnCV2FPT1KHUh?=
TE-15	M3;T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:0TWM2OD1yLki1NFk5KM7:TR?=	M4[2THNCVkeURWK=
HOP-62	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzWTWM2OD1yLki2N\|I6KM7:TR?=	NIPYcYlUSU6JUlXS
TGBC24TKB	M{jBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPnN5I5UUN3ME2wMlg3Ozh3IN88US=>	NX75bZdQW0GQR2LFVi=>
HCE-4	NFT5XZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwOEiwOlMh\|ryP	M2jqR3NCVkeURWK=
ALL-PO	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rGVmlEPTB;MD64PFE4PSEQvF2=	MnX2V2FPT1KHUh?=
KGN	NWS5[HVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LQZ2lEPTB;MD64PVk6PSEQvF2=	NXzGXZVVW0GQR2LFVi=>
ML-2	M1zYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrJSXpKSzVyPUCuPVAzPTlizszN	MlX2V2FPT1KHUh?=
ES4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXBZY1RUUN3ME2wMlkyOTJ6IN88US=>	Ml\CV2FPT1KHUh?=
SF126	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwOUS4NVkh\|ryP	NIexZ3BUSU6JUlXS
SK-N-DZ	M4LGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33BbWlEPTB;MD65OlE5QSEQvF2=	MWLTRW5IWkWU
HCC1187	M3\wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzxW\|lKSzVyPUGuNFA2ODVizszN	NHHrOWVUSU6JUlXS
DU-4475	NIeyfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFwMEG3OVYh\|ryP	NXTBSFJzW0GQR2LFVi=>
NKM-1	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTFwMEK3O\|Uh\|ryP	Ml:zV2FPT1KHUh?=
HL-60	NGi1e\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrPPZpuUUN3ME2xMlA3PTd2IN88US=>	NV:4OndpW0GQR2LFVi=>
SBC-1	M3e3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TE[WlEPTB;MT6xNlU1OiEQvF2=	MX\TRW5IWkWU
TE-10	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTFwMUK5OFYh\|ryP	M3L2VnNCVkeURWK=
ETK-1	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;I[YlrUUN3ME2xMlE{PjF\|IN88US=>	NWfObFhJW0GQR2LFVi=>
HAL-01	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37zR2lEPTB;MT6xOlcxQSEQvF2=	MY\TRW5IWkWU
BB65-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PGNGlEPTB;MT6xPFAxPSEQvF2=	MUTTRW5IWkWU
EW-1	NV\zNGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HaXGlEPTB;MT6xPFU3OiEQvF2=	MWXTRW5IWkWU
SK-NEP-1	Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi5VWhKSzVyPUGuNlEyOTFizszN	NGDNNYJUSU6JUlXS
SK-LMS-1	NUDTOXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe2WFZ{UUN3ME2xMlIzOjF{IN88US=>	MWDTRW5IWkWU
DEL	M1;hcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1u2[GlEPTB;MT6yOVY1OyEQvF2=	Mn;hV2FPT1KHUh?=
GT3TKB	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7TWlRIUUN3ME2xMlI5ODV5IN88US=>	MkjtV2FPT1KHUh?=
MOLT-16	NVvKfYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHKZolKSzVyPUGuN\|U1ODVizszN	MUPTRW5IWkWU
CMK	NGjqXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vGO2lEPTB;MT60NlEyPyEQvF2=	MnLiV2FPT1KHUh?=
NB5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFwNkSyNlkh\|ryP	Mkf4V2FPT1KHUh?=
NCI-H1963	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TySWlEPTB;MT63NFU5OyEQvF2=	MUnTRW5IWkWU
KURAMOCHI	NWLsUJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoS2TWM2OD1zLke4PVEyKM7:TR?=	M1fRc3NCVkeURWK=
TE-8	NE\4R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCyW2E5UUN3ME2xMlgxOzZ6IN88US=>	M370Z3NCVkeURWK=
NCI-H1304	NWjNeFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jPfWlEPTB;MT64N\|A4OyEQvF2=	MVzTRW5IWkWU
A101D	NGnpS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTFwOEezPVUh\|ryP	NG\5UJlUSU6JUlXS
SCLC-21H	NWX4b4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PwUWlEPTB;MT65O\|A2PyEQvF2=	NV3XRnE2W0GQR2LFVi=>
GB-1	NX7Z[4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJwMEG2OFch\|ryP	MWLTRW5IWkWU
KARPAS-45	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXEUHhKSzVyPUKuNFI3PTRizszN	NXHSb2lNW0GQR2LFVi=>
ATN-1	NX7BNXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{L1NWlEPTB;Mj6wNlg2QCEQvF2=	MnXkV2FPT1KHUh?=
NCI-H720	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTONZlkUUN3ME2yMlA3OjR2IN88US=>	NUXhfoVYW0GQR2LFVi=>
RPMI-6666	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTJwMU[yNFch\|ryP	MoPpV2FPT1KHUh?=
NB17	NHX4U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvITWM2OD1{LkK5Nlch\|ryP	NV;Ue5ZyW0GQR2LFVi=>
IST-SL1	NXjZSlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1z6[GlEPTB;Mj6yPVc3PSEQvF2=	MlXIV2FPT1KHUh?=
SH-4	NV7UbHlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\RN2lEPTB;Mj6zNlQ3QSEQvF2=	NFTZPYFUSU6JUlXS
K5	NEHhSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnPdlhKSzVyPUKuOFA{OTlizszN	NFPkXGhUSU6JUlXS
OVCAR-4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TSSGlEPTB;Mj60OlE{KM7:TR?=	M33aOXNCVkeURWK=
ACN	NX7kRmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEC0bnFKSzVyPUKuOVAzOTNizszN	MXzTRW5IWkWU
TGW	MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrCTWM2OD1{Lk[1PFMzKM7:TR?=	NEPSU4hUSU6JUlXS
NCI-H2107	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlviTWM2OD1{LkizO\|EyKM7:TR?=	MVrTRW5IWkWU
NCI-H82	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTJwOEO4N\|gh\|ryP	NGrQNXpUSU6JUlXS
SK-N-FI	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jqb2lEPTB;Mj64Olg3QCEQvF2=	NYi4OYZZW0GQR2LFVi=>
LB1047-RCC	MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLDXlY3UUN3ME2yMlg5OTJ4IN88US=>	M3fHXnNCVkeURWK=
LU-134-A	M1[5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJwOEmyOkDPxE1?	NIjhfHJUSU6JUlXS
NCI-H209	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\4UIliUUN3ME2yMlkyOjV\|IN88US=>	M{D1bXNCVkeURWK=
NOMO-1	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYH3SYZ1UUN3ME2zMlAzOjd2IN88US=>	MnvhV2FPT1KHUh?=
RH-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Py[GlEPTB;Mz6xO\|I6OSEQvF2=	NF7XbnpUSU6JUlXS
LOUCY	MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjyelhkUUN3ME2zMlE5Pjl\|IN88US=>	NVn5WHp5W0GQR2LFVi=>
TE-9	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHy1No9KSzVyPUOuNlY4OzZizszN	MVjTRW5IWkWU
PF-382	M3fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni4TWM2OD1\|LkO1O\|c5KM7:TR?=	M{LLbnNCVkeURWK=
RPMI-8402	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTNwNUi2NFMh\|ryP	MV\TRW5IWkWU
HEL	NH;6TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjmXZo2UUN3ME2zMlY{OiEQvF2=	MkLUV2FPT1KHUh?=
NOS-1	NHHRTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTNwOES3OVQh\|ryP	NVrnelhnW0GQR2LFVi=>
ES1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLpTWM2OD1\|LkmyNlk{KM7:TR?=	NGPPRXpUSU6JUlXS
NCI-H2171	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTNwOUK0NlMh\|ryP	MoP5V2FPT1KHUh?=
NCI-H747	NGq3TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTNwOUSyNlEh\|ryP	NYTXSWVCW0GQR2LFVi=>
MHH-NB-11	M4nSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M16zb2lEPTB;Mz65OVMyOiEQvF2=	NHK3NlJUSU6JUlXS
MZ1-PC	MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETUOVdKSzVyPUOuPVkzPCEQvF2=	NHvRUZNUSU6JUlXS
MMAC-SF	NHnx[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTRwMEK0Olch\|ryP	NH:0N4FUSU6JUlXS
NMC-G1	NE[zNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPaPVA1UUN3ME20MlIzPzJ\|IN88US=>	MUHTRW5IWkWU
SW872	NVLUSINUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGG5V4VKSzVyPUSuN\|Q{PCEQvF2=	M37Y[XNCVkeURWK=
TE-12	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTRwNU[zPVQh\|ryP	M1vHVnNCVkeURWK=
LU-139	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTRwNkG4N\|Uh\|ryP	Mn3FV2FPT1KHUh?=
HC-1	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[0[JFKSzVyPUSuOlk1QTRizszN	M{[yU3NCVkeURWK=
COR-L279	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTRwN{W4PVEh\|ryP	MkW5V2FPT1KHUh?=
SF268	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvuTWM2OD12Lke5PVE3KM7:TR?=	M4LWXHNCVkeURWK=
MC-CAR	NH3L[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnNPZNZUUN3ME21MlA3PzV5IN88US=>	MmXDV2FPT1KHUh?=
TK10	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTVwM{W0Olkh\|ryP	MmDKV2FPT1KHUh?=
TE-1	NHrCZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;aSIJbUUN3ME21MlQ6ODB2IN88US=>	NHzNNmdUSU6JUlXS
NCI-H2126	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHX3RYZKSzVyPUWuOlQ2PzRizszN	NH7RTXNUSU6JUlXS
Daudi	NWXFSno6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLHVZRkUUN3ME21MlY6OTJizszN	M4S5O3NCVkeURWK=
NCI-H1648	NHXOSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrkTWM2OD13LkixOFU1KM7:TR?=	M1PDVnNCVkeURWK=
OS-RC-2	NWj3T2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTVwOUi1PVch\|ryP	NETQVoNUSU6JUlXS
DJM-1	NXThWYROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPaTWM2OD14LkO0OlY3KM7:TR?=	M2jJOnNCVkeURWK=
LS-1034	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrWXYlKSzVyPU[uO\|U3PiEQvF2=	NFO2eolUSU6JUlXS
NCI-H1581	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTZwN{i0NFUh\|ryP	MnrxV2FPT1KHUh?=
UACC-257	M4HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{G5cGlEPTB;Nz6wOFUyOiEQvF2=	M1jRSXNCVkeURWK=
KM-H2	NFq4bWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTdwMUi0OVch\|ryP	MYfTRW5IWkWU
NCI-H1436	NWjqR25[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{P5ZmlEPTB;Nz62PVk{OiEQvF2=	MmHRV2FPT1KHUh?=
IA-LM	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S4WmlEPTB;Nz64OVkh\|ryP	Mn\sV2FPT1KHUh?=
NCI-H526	M3HaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\MS5BKSzVyPUiuNlU3OzdizszN	MoLXV2FPT1KHUh?=
GCIY	M2HseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4[3N2lEPTB;OD6zOlk3PSEQvF2=	NHTISJlUSU6JUlXS
CP67-MEL	NYDSXWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT0TWM2OD16LkWzNlYh\|ryP	Mn60V2FPT1KHUh?=
KALS-1	M3vzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fEe2lEPTB;OD64N\|g2OSEQvF2=	M2C1fnNCVkeURWK=
NCI-H1770	M330XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmP1TWM2OD16LkmwNlY2KM7:TR?=	NFHkOY9USU6JUlXS
8-MG-BA	M1HzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTlwM{K4OFQh\|ryP	NUDNNmdZW0GQR2LFVi=>
KY821	NGfofZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rZVmlEPTB;OT63O\|Q5PCEQvF2=	NHnaTGhUSU6JUlXS
SNB75	NF\tWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3ITWM2OD1zMD6wO\|Yh\|ryP	MW\TRW5IWkWU
NCCIT	NXHPbmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[2TWM2OD1zMT6wOVgzKM7:TR?=	MWjTRW5IWkWU
SJSA-1	M1vQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELycVVKSzVyPUGxMlI5QTFizszN	M3j6cnNCVkeURWK=
LB373-MEL-D	NITmOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn6c4h2UUN3ME2xNU4{QDJ5IN88US=>	NG\hZXZUSU6JUlXS
TALL-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHz[oRKSzVyPUGxMlQxPThizszN	NEHSOWhUSU6JUlXS
NB69	NEPweoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDXS3ZKSzVyPUGxMlc4ODVizszN	MXrTRW5IWkWU
NCI-H1355	M1jXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfpbWd1UUN3ME2xNU46PDJ4IN88US=>	NH3JXpJUSU6JUlXS
DMS-153	M1XLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWS4dIhCUUN3ME2xNk4xPDJ4IN88US=>	MnP0V2FPT1KHUh?=
OPM-2	NXTk[pdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3XTWJ2UUN3ME2xNk4yPTl4IN88US=>	NXPjfGFTW0GQR2LFVi=>
NB1	NYf5fFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHCVWhKSzVyPUGyMlI6KM7:TR?=	NUnPTZpsW0GQR2LFVi=>
A3-KAW	NEXnUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF{LkOyN\|Yh\|ryP	NVT0W\|RxW0GQR2LFVi=>
NCI-H1882	M{nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvkU4R2UUN3ME2xNk41ODZ4IN88US=>	NIHv[I5USU6JUlXS
KG-1	NWD1UoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX35NW41UUN3ME2xNk43PTR3IN88US=>	MYjTRW5IWkWU
LC4-1	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NID1dGNKSzVyPUGyMlc4ODZizszN	M3\CRnNCVkeURWK=
HCE-T	M4flRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTF\|LkCwOFkh\|ryP	NYXTRXk3W0GQR2LFVi=>
NEC8	NYryUZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPZTWM2OD1zMz6xNFM5KM7:TR?=	NEC3OpBUSU6JUlXS
IST-MEL1	NG[4OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne0TWM2OD1zMz61O\|g5KM7:TR?=	M4fhRXNCVkeURWK=
EW-3	NFnheVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIe3emFKSzVyPUGzMlc1ODJizszN	NVzLU4VtW0GQR2LFVi=>
CTB-1	NVvoVWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDi[pdKSzVyPUG0MlA{OjlizszN	M3j0VnNCVkeURWK=
LS-123	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnflTWM2OD1zND6xOVg5KM7:TR?=	NUDqbnQ5W0GQR2LFVi=>
NCI-H1417	NUn1do1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLCOnNmUUN3ME2xOE4{ODV{IN88US=>	MVvTRW5IWkWU
MZ7-mel	NEi1VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;lVVBmUUN3ME2xOE41PDN\|IN88US=>	M2PjXHNCVkeURWK=
JiyoyeP-2003	M{HzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWn4RXhZUUN3ME2xOU43OzJ4IN88US=>	M1rBc3NCVkeURWK=
ES6	Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLsXIhnUUN3ME2xOk4zOzZzIN88US=>	MYDTRW5IWkWU
HH	M1LkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\aOmdKSzVyPUG3MlE6PjNizszN	MX;TRW5IWkWU
SF539	NVm4dXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LneWlEPTB;MUeuPVkzOiEQvF2=	MnXoV2FPT1KHUh?=
Calu-6	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7YTWM2OD1zOT6yN\|kh\|ryP	NWTDbJpNW0GQR2LFVi=>
SK-MM-2	NIH0PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\mTWM2OD1zOT61OVUh\|ryP	NF25dW1USU6JUlXS
IST-MES1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:y[\|U2UUN3ME2xPU43PjZ\|IN88US=>	NHO4d4tUSU6JUlXS
GI-ME-N	M4Ptfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DFNWlEPTB;MUmuPFIzPyEQvF2=	M1f6d3NCVkeURWK=
CAL-148	NEXh[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3JTWM2OD1{MD65PVM1KM7:TR?=	MUTTRW5IWkWU
EVSA-T	M4nJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXHUpN4UUN3ME2yNU4yPDl7IN88US=>	NHn6dJhUSU6JUlXS
LP-1	M2LTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TEOmlEPTB;MkGuN\|Q{OiEQvF2=	M4LNRnNCVkeURWK=
BOKU	MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXLTWM2OD1{MT60OVM{KM7:TR?=	Ml:wV2FPT1KHUh?=
KLE	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVu3Xo02UUN3ME2yNk4yQTB\|IN88US=>	MXzTRW5IWkWU
LB831-BLC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;BdmxKSzVyPUK1MlE2OjZizszN	NFj6N3hUSU6JUlXS
NCI-H889	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXvTWM2OD1{NT6xPVMyKM7:TR?=	M3;FTHNCVkeURWK=
REH	NEXobJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\ZdGlEPTB;MkWuOFY4OSEQvF2=	MnTiV2FPT1KHUh?=
KP-N-RT-BM-1	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTJ3LkS3OVIh\|ryP	NYDwfGVMW0GQR2LFVi=>
MPP-89	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJ3LkWzNVQh\|ryP	NYTjS5NGW0GQR2LFVi=>
no-11	NGDaOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjQTWM2OD1{NT63OFch\|ryP	NWnQWW5PW0GQR2LFVi=>
NCI-H748	M1myXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTQXIdDUUN3ME2yOU44PjJ5IN88US=>	MV7TRW5IWkWU
LB2518-MEL	M4PMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\DTWM2OD1{Nz6xO\|c{KM7:TR?=	NGf1e45USU6JUlXS
TGBC1TKB	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjJPVZmUUN3ME2yO{42PTh3IN88US=>	MlH2V2FPT1KHUh?=
MHH-PREB-1	NV2y[21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{X6d2lEPTB;MkiuNFc{PCEQvF2=	Ml7RV2FPT1KHUh?=
MZ2-MEL	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PxXmlEPTB;MkiuOlE1OyEQvF2=	NYTLfXRyW0GQR2LFVi=>
U-266	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDNdoJKUUN3ME2yPE43OzZ4IN88US=>	NXHmOIN1W0GQR2LFVi=>
SNU-C1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTJ6Lkm0N{DPxE1?	MY\TRW5IWkWU
SW962	MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDIW5ZGUUN3ME2zNE4zPzR5IN88US=>	M3\SdHNCVkeURWK=
Raji	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTNyLkW1PVIh\|ryP	MkPJV2FPT1KHUh?=
KNS-42	NIjLdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTGOIxNUUN3ME2zNE45QTV4IN88US=>	MXjTRW5IWkWU
LB996-RCC	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS4bFJKSzVyPUOxMlE4ODJizszN	MXvTRW5IWkWU
CHP-126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3O[ndKSzVyPUOxMlE6QDRizszN	MlvCV2FPT1KHUh?=
RXF393	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoK0TWM2OD1\|Mj60PVch\|ryP	NIrIOodUSU6JUlXS
COLO-684	M2nxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTN{Lk[0N\|gh\|ryP	NUPoN4p4W0GQR2LFVi=>
A704	NVztS4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvvZ4VKSzVyPUOzMlU2OzhizszN	M2CyZ3NCVkeURWK=
A253	M4jUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzuTWM2OD1\|Mz61PFUzKM7:TR?=	NXLtN5RrW0GQR2LFVi=>
KNS-81-FD	NXXJdWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjFTWM2OD1\|ND61OFU3KM7:TR?=	MWXTRW5IWkWU
TE-441-T	M2LydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTN2Lk[zO\|Eh\|ryP	MX7TRW5IWkWU
HCC2157	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrsVI1CUUN3ME2zOU41PjF7IN88US=>	NHOxXYRUSU6JUlXS
ES3	NHHRcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTN4Lk[3OUDPxE1?	NWDh[lFWW0GQR2LFVi=>
NCI-H1155	MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7iTWM2OD1\|Nz64NVUh\|ryP	NYnQR4hjW0GQR2LFVi=>
SNU-C2B	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHaR5g5UUN3ME2zPE4yPjV2IN88US=>	NXrkdm9EW0GQR2LFVi=>
JAR	NV73b21kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf5U\|NKSzVyPUO4MlI1PDlizszN	M3\JfXNCVkeURWK=
GDM-1	M1TtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17KbGlEPTB;M{iuPVEyPiEQvF2=	M1;4SXNCVkeURWK=
KU812	NFrj[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPEWpFmUUN3ME20NU42ODdizszN	Mn3LV2FPT1KHUh?=
BC-1	M{LQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfCb\|hSUUN3ME20Nk43PzNzIN88US=>	MnPWV2FPT1KHUh?=
GI-1	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDDcGtKSzVyPUSyMlkyQTJizszN	MYnTRW5IWkWU
NCI-H1694	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXvTWM2OD12ND65OFczKM7:TR?=	M4m4SHNCVkeURWK=
DG-75	NEfze4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoraTWM2OD12NT6xOVc4KM7:TR?=	NYT0cpU{W0GQR2LFVi=>
COR-L88	Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLyTWM2OD12NT6yO\|c5KM7:TR?=	M3fpcXNCVkeURWK=
LS-513	NX\0NlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfJ[XFKSzVyPUS1MlkyPTZizszN	M1LDc3NCVkeURWK=
HD-MY-Z	M2e5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFGzRpNKSzVyPUS2MlQ3OTJizszN	MoL4V2FPT1KHUh?=
L-363	NX3kOJRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XYfGlEPTB;NE[uPFgyKM7:TR?=	NUPROXNlW0GQR2LFVi=>
TE-6	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;5VGlEPTB;NEiuOFQ3KM7:TR?=	M4m5UnNCVkeURWK=
NCI-H345	M3XtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTBTIFmUUN3ME20PE41PjhizszN	MnP2V2FPT1KHUh?=
TE-5	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[zTlVKSzVyPUS5MlcyOThizszN	M3flTXNCVkeURWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DLK / p-MKK7 / MKK7 / p-JNK / JNK ; PubMed: 23431148 Proc Natl Acad Sci U S A Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. p-AURKA / AURKA / Survivin ; PubMed: 28218735 Oncogenesis BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. YAP; PubMed: 31160567 Cell Death Dis Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; PubMed: 21600017 J Transl Med NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.	23431148 28218735 31160567 21600017
Immunofluorescence	α-tubulin / Aurora-A ; PubMed: 21600017 J Transl Med The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.	21600017
Growth inhibition assay	Cell viability; PubMed: 21600017 J Transl Med VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, p < 0.05, *p < 0.01, compared to control.	21600017

In vivo

VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. ^[1]

Protocol

Kinase Assay: ^[3]	- Collapse Kinase inhibition assays: The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K _i = IC50 / (1 + [S]/K_d), where [S] = [ATP] = 2.2 mM, and K_d (of ATP to Abl) = 70 μM. These values are calculated assuming a K_d (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research: ^[2]	- Collapse Cell lines: CAL-62 cells Concentrations: 5-500 nM Incubation Time: 4 days Method: The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500 nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500 nM). The cells are pulse labeled with 30 mM BrdU for 2 hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells Dosages: 50 mg/kg, 75 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

- Collapse

Solubility (25°C)

In vitro	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Molecular Weight	464.59
Formula	C₂₃H₂₈N₈OS
CAS No.	639089-54-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CN1CCN(CC1)C2=NC(=NC(=C2)NC3=N[NH]C(=C3)C)SC4=CC=C(NC(=O)C5CC5)C=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitors

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitors

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.
Barasertib (AZD1152-HQPA)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)